OUR SCIENCE

Tech and Hearts Orbiting Recovery

Pioneering targeted therapies
against cancer cachexia and immuno-oncology.

OUR APPROACH

THOR Therapeutics focuses on the GDF15-GFRAL signaling axis - a receptor-ligand pathway activated by cancer that drives cachexia, sympathetic hyperactivation and immune suppression. We develop GFRAL-blocking monoclonal antibodies and antisense oligonucleotides that target the D3 domain of GFRAL to disrupt GDF15-GFRAL-RET signaling at its source. Our platform integrates structural biology, neurobiology and AI-based antibody design to engineer candidates with differentiated mechanisms of action.

Developing first-in-class GFRAL-blocking therapies for cancer cachexia and beyond.
  • Antisense Oligonucleotide Engineering
  • Structural Biology & Antibody Design
  • AI-Driven Drug Discovery

OUR DISCOVERY STRATEGY

We advance two complementary modalities in parallel - anti-GFRAL antibodies and antisense oligonucleotides, validated in orthotopic pancreatic and colon cancer models. Internal innovation is strengthened by an advisory network with direct experience at Novo Nordisk, Evotec, Novartis and EPFL, ensuring our programs meet global industry standards from discovery through IND-enabling studies.